Skip to content
Roboearth – Lifestyle
Author:
Ambros Therapeutics, Inc.
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
June 11, 2026
Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1
June 8, 2026
Ambros Therapeutics Announces Notice of Allowance for New U.S. Patent Application Covering Neridronate for Complex Regional Pain Syndrome Type 1
March 31, 2026